• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
ImmunoVaccine Technologies Inc. - Product Pipeline Review - Q4 2010 Product Image

ImmunoVaccine Technologies Inc. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • Region: Global
  • 41 pages
  • GlobalData

ImmunoVaccine Technologies Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “ImmunoVaccine Technologies Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ImmunoVaccine Technologies Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ImmunoVaccine Technologies Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, READ MORE >



List of Tables
List of Figures
ImmunoVaccine Technologies Inc. Snapshot
ImmunoVaccine Technologies Inc. Overview
Key Information
Key Facts
ImmunoVaccine Technologies Inc. – Research and Development Overview
Key Therapeutic Areas
ImmunoVaccine Technologies Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
ImmunoVaccine Technologies Inc. – Pipeline Products Glance
ImmunoVaccine Technologies Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
ImmunoVaccine Technologies Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
ImmunoVaccine Technologies Inc. – Drug Profiles
DPX-0907
Product Description
Mechanism of Action
R&D Progress
DepoVax HPV Formulation
Product Description
Mechanism of Action
R&D Progress
DepoVax Pandemic Influenza vaccine
Product Description
Mechanism of Action
R&D Progress
Hepatitis B vaccine Program
Product Description
Mechanism of Action
R&D Progress
IRX-2 + DepoVax
Product Description
Mechanism of Action
R&D Progress
DepoVax Pseudomonas aeruginosa vaccine
Product Description
Mechanism of Action
R&D Progress
ImmunoVaccine Technologies Inc. – Pipeline Analysis
ImmunoVaccine Technologies Inc. – Pipeline Products by Therapeutic Class
ImmunoVaccine Technologies Inc. Pipeline Products By Target
ImmunoVaccine Technologies Inc. – Pipeline Products by Route of Administration
ImmunoVaccine Technologies Inc. – Pipeline Products by Molecule Type
ImmunoVaccine Technologies Inc. – Recent Pipeline Updates
ImmunoVaccine Technologies Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 17, 2010: Immunovaccine Announces Phase I/II Clinical Plan For DPX-Survivac To Target Ovarian Cancer
Oct 13, 2010: Immunovaccine And Defence Research And Development Canada Advance Potential Melioidosis Vaccine Candidate
Oct 05, 2010: Immunovaccine And IRX Therapeutics Collaborate On Cancer Immunotherapies
Sep 28, 2010: Immunovaccine To Present Preclinical Data On DepoVax Therapeutic Cancer Vaccine At iSBTc Conference 2010
Jul 12, 2010: Immunovaccine Licenses Clinical Stage Cancer Vaccine From Merck KGaA
Apr 05, 2010: Immunovaccine Announces Publication Of DPX-0907 Preclinical Study
Mar 30, 2010: Immunovaccine Starts Patient Recruitment For Phase I Trial Of DPX-0907 Cancer Vaccine
Mar 30, 2010: Immunovaccine Starts Patient Recruitment For Phase I Trial Of DPX-0907 Cancer Vaccine
Mar 30, 2010: Immunovaccine Starts Patient Recruitment For Phase I Trial Of DPX-0907 Cancer Vaccine
Dec 10, 2009: Immunovaccine Inc. Announces Approval Of Investigational Drug Application For Its Therapeutic Cancer Vaccine, DPX-0907
Financial Deals Landscape
ImmunoVaccine Technologies Inc., Deals Volume Summary, 2004 to YTD 2010
ImmunoVaccine Technologies Inc., Deals Summary By Region, 2004 to YTD 2010
ImmunoVaccine Technologies Inc., Deals Summary, 2004 to YTD 2010
ImmunoVaccine Technologies Inc. Detailed Deal Summary
ImmunoVaccine Enters Into Research Agreement With National Cancer Institute
ImmunoVaccine Technologies Enters Into Agreement With Scancell
Licensing Agreements
Immunotope Enters Into Licensing Agreement With ImmunoVaccine Technologies
Pharmexa Enters Into Licensing Agreement With ImmunoVaccine Technologies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS